RxDoctor Payments Data

Ralph Santoro, MD

Internal Medicine · Cranston, RINPI 1710098249

Payments from drug & device makers

$2,423in general payments, 2019–2025

Across 120 payments — averaging $20.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$326
  • Otsuka America Pharmaceutical, Inc.$267
  • Neurocrine Biosciences, Inc.$213
  • Bayer$167
  • Lundbeck LLC$162
  • Lilly USA, LLC$149
  • plus $1K from 27 others

What the payments were for

  • Speaking & faculty fees$361%
  • Food & beverage$2,28794%
  • Education$1014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,423 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$227,127
Medicare patients
460
Services billed
2,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,258$427,798
JardianceEmpagliflozin405$171,258
TrulicityDulaglutide156$145,435
XareltoRivaroxaban287$108,750
Invega SustennaPaliperidone Palmitate35$99,880
IngrezzaValbenazine Tosylate16$62,931
TradjentaLinagliptin152$50,615
MyrbetriqMirabegron183$49,974
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$41,577
Atorvastatin Calcium2,208$38,977
Breo ElliptaFluticasone/Vilanterol88$37,923
JanuviaSitagliptin Phosphate99$37,409
OzempicSemaglutide32$34,507
Spiriva RespimatTiotropium Bromide60$33,674
EntrestoSacubitril/Valsartan78$33,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$77$427,7981,258 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$19$270,234644 claims
Johnson & JohnsonXarelto, Invega Sustenna$54$208,630322 claims
Lilly USA, LLCTrulicity, Mounjaro$149$177,385182 claims
Neurocrine Biosciences, Inc.Ingrezza$213$62,93116 claims
Astellas Pharma US IncMyrbetriq$326$49,974183 claims
NovartisEntresto$116$33,26378 claims
AstraZenecaFarxiga$71$22,55347 claims
AbbVieVraylar$43$20,73329 claims
Sumitomo Pharma America, Inc.Gemtesa$45$17,15858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →